logologo
QuantliQuantli

ImmuCell Corp

ICCC

NASDAQ

Biotechnology

$10.05

USD

-0.85 (-7.80%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $100.42M

Volume 92.0K

Price (USD)
Price (USD)

About ImmuCell Corp

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 73 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

CEO

Mr. Olivier te Boekhorst

HQ

Portland, MAINE, US

Founded

1987

Employees

73

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

6 metrics our research team weighs before forming a view on ICCC.

Based on Quantli research · SEC filings · as of Q1 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

9.6%

-18.6 pp

Gross Margin (TTM)

42.6%

+9.6 pp

Operating Margin (TTM)

8.4%

+9.2 pp

Net Margin (TTM)

-1.8%

-0.8 pp

ROE (TTM)

-1.9%

-0.9 pp

Free Cash Flow (TTM)

$3.38M

+328.0%

Financial Snapshot

Full Financials

Revenue

$29.93M

+9.6%

YoY

Gross Margin

43%

TTM

+29.2%

YoY

Net Income

$-545,403

-100.7%

YoY

Operating Cash Flow

$4.47M

+195.7%

YoY

Key Statistics

Open

$10.72

Previous Close

$10.90

Day Range

$9.75 - $10.72

52 Week Range

$4.52 - $12.10

Volume

92.0K

Average Volume (10 Days)

20.0K

Dividend Yield

Valuation Measurement

Market Cap

$100.42M

P/E Ratio (TTM)

P/S Ratio (TTM)

3.35

Price / Book

3.45

Financial Highlights

Profit Margin

-1.8%

Return on Assets

-1.2%

Return on Equity

-1.9%

Revenue (TTM)

$29.93M

Net Income (TTM)

$-545,403

Diluted EPS (TTM)

-$0.06

Total Cash (MRQ)

$6.81M

Levered FCF (TTM)

$3.38M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Go deeper on ICCC

Similar Stocks

ALDX

Aldeyra Therapeutics Inc

$1.56

+8.3%

BMEA

Biomea Fusion Inc

$1.32

+3.1%

CTOR

Citius Oncology Inc

$0.9100

+10.0%

RLYB

Rallybio Corp

$16.99

+0.2%

GANX

Gain Therapeutics Inc

$2.12

-2.1%

ACRV

Acrivon Therapeutics Inc

$1.95

+5.4%

KLRS

Kalaris Therapeutics Inc

$4.08

+5.2%

FBIO

Fortress Biotech Inc

$2.93

-1.7%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 11